Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PEP-DC vaccine + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- Centre Hospitalier Universitaire Vaudois
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Oral
01
Overview
PEP-DC is an autologous dendritic cell vaccine loaded with personalized peptides (neoantigens) identified from a patient's tumor. Developed by the Centre Hospitalier Universitaire Vaudois (CHUV), it is designed to treat advanced or metastatic non-small cell lung cancer (NSCLC). The vaccine utilizes the patient's own dendritic cells to present tumor-specific antigens to the immune system, thereby inducing a targeted T-cell response. In clinical trials, it is administered in combination with low-dose cyclophosphamide, which functions as an immunomodulator to deplete regulatory T cells (Tregs) and overcome tumor-induced immunosuppression.
- Other names
- Personalized peptide-pulsed dendritic cell vaccineAutologous dendritic cell vaccine loaded with personalized peptides
02
Targets
DNA
Beyond the preview
Go deeper on PEP-DC vaccine + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PEP-DC vaccine + cyclophosphamide.